CG Oncology (NASDAQ:CGON - Get Free Report) had its target price lifted by equities research analysts at HC Wainwright from $100.00 to $115.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 35.65% from the company's previous close.
A number of other analysts have also commented on CGON. Wall Street Zen raised shares of CG Oncology from a "strong sell" rating to a "sell" rating in a research report on Saturday, November 7th. Piper Sandler raised their target price on shares of CG Oncology from $82.00 to $85.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Guggenheim lowered their price target on shares of CG Oncology from $90.00 to $89.00 and set a "buy" rating on the stock in a research note on Monday, November 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of CG Oncology in a research note on Thursday, October 15th. Finally, Wedbush boosted their price target on shares of CG Oncology from $80.00 to $84.00 and gave the stock an "outperform" rating in a research report on Friday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $91.78.
Read Our Latest Analysis on CG Oncology
CG Oncology Stock Performance
Shares of CG Oncology stock opened at $84.78 on Tuesday. The business's 50 day simple moving average is $68.24 and its 200 day simple moving average is $66.70. CG Oncology has a 52-week low of $37.01 and a 52-week high of $93.95. The firm has a market cap of $7.57 billion, a PE ratio of -30.72 and a beta of 0.35.
CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.19. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.55 million. As a group, equities research analysts predict that CG Oncology will post -3.00 EPS for the current year.
Insider Activity at CG Oncology
In other news, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $62.06, for a total transaction of $62,060.00. Following the transaction, the director directly owned 1,000 shares in the company, valued at $62,060. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.80% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On CG Oncology
A number of institutional investors and hedge funds have recently modified their holdings of the company. Aquatic Capital Management LLC increased its position in CG Oncology by 111.2% during the third quarter. Aquatic Capital Management LLC now owns 24,435 shares of the company's stock worth $1,732,000 after buying an additional 12,867 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of CG Oncology by 32.5% in the third quarter. Goldman Sachs Group Inc. now owns 1,136,464 shares of the company's stock valued at $80,564,000 after buying an additional 278,751 shares during the last quarter. Toronto Dominion Bank lifted its position in shares of CG Oncology by 177.7% in the third quarter. Toronto Dominion Bank now owns 798,676 shares of the company's stock valued at $56,618,000 after buying an additional 511,044 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of CG Oncology in the third quarter valued at approximately $4,665,000. Finally, Marshall Wace LLP lifted its position in shares of CG Oncology by 179.8% in the third quarter. Marshall Wace LLP now owns 11,708 shares of the company's stock valued at $830,000 after buying an additional 7,523 shares during the last quarter. 26.56% of the stock is owned by institutional investors.
Key Stories Impacting CG Oncology
Here are a few of the latest stories about CGON:
- Positive Sentiment: The treatment’s reported safety profile was favorable: no Grade 3 or higher treatment-related adverse events or treatment-related discontinuations. The results strengthen the case for cretostimogene as a potential treatment across a broader range of bladder-cancer patients. CG Oncology announcement
- Positive Sentiment: CG Oncology expects to use PIVOT-006 data in a second biologics license application (BLA), targeted for Q2 2027. The company also plans to broaden its initial BLA for BCG-unresponsive disease to include high-grade papillary-only patients, with submission completion expected by March 2027.
- Neutral Sentiment: The results are topline and based on preliminary analysis. Regulatory approval is not assured; the FDA could request more data or studies, or approve a narrower label. The full trial results are scheduled for presentation at the Society of Urologic Oncology meeting on December 2.
About CG Oncology
(
Get Free Report)
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company's research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.